Filing
2nd Quarter - Report
Bills named in this filing
1
Lobbying activity
3
Matters related to access to and pricing of plasma derived products and matters affecting the Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Matters affecting plasma donation and potential plasma shortages. Issues related to PAHPA.
Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.